Evaluation of severity of predominantly non-dopaminergic symptoms in Parkinson's disease: The SENS-PD scale.

INTRODUCTION In spite of the multisystem nature of Parkinson's disease (PD), the formal assessment of its impairments is focused on symptoms predominantly reflecting degeneration of dopaminergic neurons. The aim of this study was to develop a valid and reliable rating scale of predominantly non-dopaminergic (PND) symptoms, which can be used as an additional measure of severity and progression of PD. METHODS Using data of the PROPARK (N = 396) and ELEP (N = 365) cohorts, three items were selected from each of six selected PND domains (cognitive impairment, depressive symptoms, excessive daytime sleepiness, psychotic symptoms, autonomic dysfunction and Postural-Instability-and-Gait-Difficulty), based on item-total correlations. Hereafter, we evaluated reliability and validity of the resulting scale. RESULTS The 18-item PND scale showed to be reliable and valid. Cronbach's alpha was 0.83. Principal component analysis using the six domain scores resulted in one factor, justifying the calculation of a sum score. Correlation coefficients of the sum score with severity of non-motor symptoms (non-motor part of MDS-UPDRS), motor symptoms (SPES/SCOPA scale), and Hoehn and Yahr stage were 0.63, 0.41 and 0.48, respectively (p < 0.001). CONCLUSION We developed a short, reliable and valid scale to evaluate severity of PND symptoms in PD. The score is expected to be largely insensitive to dopaminergic effects and may therefore more accurately reflect severity and progression of the underlying disease than currently used dopamine-sensitive measures. In combination with assessment of predominantly dopaminergic (motor) symptoms, a broad yet concise evaluation of PD is obtained, which better captures the widespread clinical consequences of the multisystem disease.

[1]  J. Marinus,et al.  SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson's disease. , 2011, Parkinsonism & related disorders.

[2]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[3]  A M Stiggelbout,et al.  Patient-reported autonomic symptoms in Parkinson disease , 2007, Neurology.

[4]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[5]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[6]  A M Stiggelbout,et al.  A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  C. McHorney,et al.  Individual-patient monitoring in clinical practice: are available health status surveys adequate? , 1995, Quality of Life Research.

[8]  Paolo Barone,et al.  The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[9]  M. Hoehn,et al.  Parkinsonism , 1998, Neurology.

[10]  A. Lang,et al.  Pharmacological treatment of Parkinson disease: a review. , 2014, JAMA.

[11]  J. Marinus,et al.  Patterns of motor and non-motor features in Parkinson’s disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  A. Fasano,et al.  Gastrointestinal dysfunction in Parkinson's disease , 2003, The Lancet Neurology.

[13]  J. Assmus,et al.  Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease , 2013, Acta neurologica Scandinavica.

[14]  R. D. de Haan,et al.  Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD , 2004, Neurology.

[15]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[16]  K. Jellinger Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts , 2012, Movement disorders : official journal of the Movement Disorder Society.

[17]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[18]  Johan Marinus,et al.  Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.

[19]  Gert Jan Lammers,et al.  Assessment of sleep and sleepiness in Parkinson disease. , 2003, Sleep.

[20]  J. Marinus,et al.  Importance of nondopaminergic features in evaluating disease severity of Parkinson disease , 2014, Neurology.

[21]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.

[22]  Martina Mancini,et al.  Levodopa Is a Double‐Edged Sword for Balance and Gait in People With Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[23]  A. Stiggelbout,et al.  Evaluation of the Hospital Anxiety and Depression Scale in Patients With Parkinson's Disease , 2002, Clinical neuropharmacology.

[24]  Dagmar Verbaan,et al.  Assessment of psychiatric complications in Parkinson's disease: The SCOPA‐PC , 2007, Movement disorders : official journal of the Movement Disorder Society.

[25]  Andy P. Field,et al.  Discovering Statistics Using SPSS , 2000 .

[26]  Grupo Elep Estudio longitudinal de pacientes con enfermedad de Parkinson (ELEP) : objetivos y metodología , 2006 .

[27]  Kathleenl N. Lohr,et al.  Assessing health status and quality-of-life instruments: Attributes and review criteria , 2002, Quality of Life Research.

[28]  A M Stiggelbout,et al.  Assessment of cognition in Parkinson’s disease , 2003, Neurology.

[29]  R. Snaith,et al.  The hospital anxiety and depression scale. , 2013, Acta psychiatrica Scandinavica.

[30]  D. Watson,et al.  Constructing validity: Basic issues in objective scale development , 1995 .